Search PubMed⌕ Search

Biomedical subjects

A Goldhirsch

Publications and source records attributed to A Goldhirsch.

At least 307 records · Page 17Linked to original sources
PubMed1981

[Treatment and prognosis of superior vena caval syndrome in small-cell anaplastic carcinoma of the lung (author's transl)].

One hundred and forty nine consecutive patients with small-cell anaplastic carcinoma of the lung were studied retrospectively. 19 patients (13%) presented with superior vena caval obstruction, 11 further patients (7%) developed this complication during the course of their disease. 16 patients presenting with superior vena caval syndrome were treated with chemotherapy alone and 13 patients responded. Due to suboptimal chemotherapy for current standards 7 of the 13 successfully treated patients (54%) relapsed after a median of 4.5 months. 3 patients were effectively retreated with another chemotherapy combination, 4 patients with radiation therapy. Superior vena caval obstruction is a frequent complication of small-cell anaplastic carcinoma of the lung. It can be treated effectively with combination chemotherapy.

Antineoplastic Agents↗
PubMed1981

[Central nervous system metastases in small cell lung cancer].

Forty of 156 patients (26%) with small cell lung cancer developed central nervous system metastases (CNS metastases) in the course of the disease. CNS metastases were found in 8 patients at the time of the initial diagnosis and 32 patients had subsequent CNS involvement. CNS metastases were usually concurrent with disease progression at other sites and became more frequent as survival increased. With a median survival of 6 months in 1973 19% of patients developed CNS metastases as compared to 35% in 1978, when median survival had increased to 9.5 months. The value of prophylactic cranial irradiation is discussed.

Brain Neoplasms↗
PubMed1981

Cis-dichlorodiammineplatinum (II) and VP 16-213 combination chemotherapy for non-small cell lung cancer.

Twenty-three patients with non-small cell lung cancer were treated with a combination of cis-dichlorodiammineplatinum (II) 100 mg/m2 IV on day 1 and VP 16-213 80 mg/m2 IV on days 1-3. Eighteen patients are evaluable for response. Seven partial remissions with a median duration of 3 months (range, 1-13+) have been observed. Three patients exhibit stable disease, and eight patients show tumor progression. Overall survival was 5+ months (range, 1-13+); 7.5 months (range, 3-13+) for responders and 3+ months (range, 1-9+) for non-responders. Hematologic toxicity was acceptable, but poor subjective tolerance (nausea, vomiting, loss of appetite) was the main factor limiting treatment duration.

Adenocarcinoma↗
PubMed1980

[Ovarian carcinoma: new prognostic and therapeutic viewpoints].

Some recently developed concepts concerning the management of ovarian cancer are discussed. Cytoreductive surgery to debulk the tumor to a minimum, even in those cases which were considered inoperable in the past, improves the chances for cure. Adjuvant radiotherapy or combination chemotherapy with new drugs have proved highly effective in inducing complete remission and potential cures in these patients. The definition and better understanding of prognostic criteria play a primary role in the selection of treatment. In designing the strategy for adequate treatment, the following points are of major importance: (1) exact definition of tumor spread as determined by accurate surgical staging; (2) histologic and cytologic grading; and (3) evaluation of response.

Alkylating Agents↗
PubMed1980

[Phase-II-study with vindesine (desacetyl-vinblastine-amide-sulfate) in advanced malignant diseases].

53 patients with advanced and measurable cancerr were treated with vindesine in doses of 3 mg/m2 (pretreated) and 4 mg/m2 (non pretreated) i.v. once weekly. 48 patients are evaluable for response: of 14 patients with squamous cell carcinoma of the lung, 1 partial remission (PR), 1 minor response (MR) and 1 no change (NC) were observed. In 5 patients with large cell carcinoma of the lung: 1 NC. In 3 with adenocarcinoma of the lung: 1 MR. One patient with nasopharyngeal carcinoma had progressive disease. Stable disease was observed in a patient with carcinoma of the tongue and in a patient with adenocarcinoma of the esophagus. Four patients with colorectal carcinoma had progressive disease. One MR was observed in a patient with breast cancer, while all of the other 3 patients had progressive disease. One carcinoma of the penis was stable. One MR was observed in a patient with Hodgkin's disease. One PR was observed in a case with no-Hodgkin's lymphoma. A patient with acute leukemia had progressive disease. Among 9 patients with malignant melanoma, 3 had an MR and 1 patient had stable disease. A patient with fibrosarcoma had progressive disease. Observed toxicity included leukopenia, thrombocytopenia, anemia, paresthesias, constipation, jaw pain, nausea, stomatitis, alopecia, loss of taste, pruritus and skin rash, weakness and fatigue.

Adenocarcinoma↗
PubMed1980

[Malignant melanoma: spontaneous course, therapy and prognosis].

The natural history, treatment and prognosis of malignant melanoma are reviewed. Stage, histologic level of invasion and clinical type are the most important prognostic factors. Surgical approach for treatment of the primary tumor, adjuvant therapy and treatment of advanced disease (chemotherapy, hormonal manipulation and immunotherapy) are discussed. 5-year survival rates are tabulated in relation to the most important prognostic factors.

Female↗
PubMed1980

[Kidney and urinary tract complications in tumor patients].

This review deals with renal and urinary tract complications in tumor patients. Neoplastic infiltration of the kidney and glomerular nephropathies in neoplastic diseases are discussed. Tumor obstruction of the urinary tract and renal disease due to tumor metabolites are important, potentially reversible complications. Radiation nephritis and drug-induced renal disease can often be avoided with the aid of precautionary measures. Urogenital infections in tumor patients are frequent and often due to atypical microorganisms. Guidelines for dosage modifications of antineoplastic agents in patients with renal insufficiency are summarized. Renal failure in tumor patients deserves a careful diagnostic and therapeutic approach. The potential renal and urinary tract toxicities of the different therapeutic modalities must be considered when planning therapy for cancer patients.

Alkylating Agents↗
PubMed1980

[Adjuvant chemotherapy in soft tissue sarcomas].

21 patients with soft tissue sarcomas were treated after surgery with adriamycin alone or in combination with other drugs. 13 patients had additional local radiotherapy. 12 of thde 21 patients received chemotherapy as an adjuvant to surgery. 19 patients concurrently receiving palliative treatment for advanced soft tissue sarcoma in the form of adriamycin and adriamycin combinations served as controls. Results collected to date point to an improvement in the prognosis of soft tissue sarcomas, when radical surgery is followed by intensive subsequent cytostatic treatment. However, the present results await confirmation from prospective randomized studies now taking place. Some of the side effects of this treatment were very pronounced and led to the premature interruption of the trial in 24% of cases.

Adolescent↗